First-Line Pembrolizumab Plus Niraparib in Advanced Metastatic NSCLC
Posted: Wednesday, December 16, 2020
The combination of the PARP inhibitor niraparib plus the PD-L1 inhibitor pembrolizumab induced durable responses in chemotherapy-naive patients with locally advanced metastatic non–small cell lung cancer (NSCLC). Prior research had suggested that the PARP inhibitor might interact synergistically with pembrolizumab. The results of this phase II JASPER study, conducted by Suresh Ramalingam, MD, of Emory University, Atlanta, and colleagues, were presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 1268P).
“Niraparib plus pembrolizumab induces durable responses in patients with NSCLC, with larger effects in the PD-L1–high cohort,” the investigators announced.
In this study, patients were placed into one of two cohorts based on their PD-L1 tumor proportion score (TPS). Cohort 1 comprised 17 patients with a TPS of at least 50%, and cohort 2 was made up of 21 patients with a TPS between 1% and 49%.
The confirmed objective response rate was 56.3% in cohort 1, with two complete responses, and 20% in cohort 2. Median progression-free survival and the duration of response were 8.4 months (n = 16) and 19.7 months (n = 9), respectively, for patients in cohort 1. Patients in cohort 2 had a median progression-free survival of 4.2 months (n = 20), and the duration of response was 9.4 months (n = 4).
Adverse events of grade ≥ 3 occurred in more than 10% in both cohorts. The most frequent adverse events were anemia (24% in cohort 1; 29% in cohort 2), pneumonia (24% in cohort 1; 14% in cohort 2), and fatigue (12% in cohort 1; 14% in cohort 2).
Disclosure: For full disclosures of the study authors visit www.esmo.org.
